polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride
NULYTELY (polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride) by R-Pharm US is osmotic activity [moa]. First approved in 1991.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
NULYTELY is an oral osmotic laxative solution containing polyethylene glycol 3350 with electrolytes (sodium chloride, sodium bicarbonate, potassium chloride) used for bowel preparation prior to colonoscopy and other GI procedures. It works by osmotic activity to draw water into the intestinal lumen, producing effective bowel evacuation without significant fluid or electrolyte shifts.
Mature product in decline phase with minimal Part D spending; teams focused on cost containment and generic transition management rather than growth initiatives.
Osmotic Activity
Osmotic Laxative
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NULYTELY represents a declining-stage career opportunity with limited growth prospects and minimal linked job openings; roles center on managing a mature product through commoditization and generic competition. This position suits professionals seeking stability in a cost-focused, execution-driven environment rather than innovation or market expansion.
Worked on NULYTELY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo